Navigation Links
NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
Date:9/6/2011

DeGiorgio and Ian Cook, UCLA faculty in the Departments of Neurology and Psychiatry, are the principal investigators of this project.  Together they have pioneered TNS for epilepsy, depression, post-traumatic stress disorder and other indications.

"We have already seen the safety and efficacy of our non-invasive eTNS™ therapy in prior clinical trials and look forward to the opportunity to further validate our therapy through the valuable funding provided by NINDS," said Dr. DeGiorgio.  "We are also very pleased to receive this grant knowing that NIH's highly regarded peer review process includes a rigorous review by leading medical experts."

CAUTION: The eTNS™ system is an investigational device and at this time is limited by United States law for investigational use only.

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice. Currently, NeuroSigma is focused on a number of neuromodulation therapies and through our majority-owned subsidiary, NSVascular, on Thin-Film Nitinol covered stents for endovascular applications. NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property that is based on technology licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS. For more information about NeuroSigma, please visit our website at http://www.neurosigma.com.


'/>"/>
SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. NeuroSigma, Inc. Retains CCG Investor Relations
4. Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or Off-The-Shelf Stem Cell Treatment for Heart Attacks
5. Lupin Receives Final Approval to Market Generic Ultram® ER
6. Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants
7. Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
8. Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
9. Simceres Iremod Receives SFDA New Drug Approval
10. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
11. WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD and EU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
(Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
(Date:5/19/2013)... 2013 Healthcare leaders will gather at ... the Walt Disney World Swan and Dolphin in Orlando, ... innovation, care delivery and healthcare reform and implementation. , ... healthcare markets, with consolidation, efficiency and reduced ... Todd Ebert, Amerinet president and CEO. “There is a ...
(Date:5/19/2013)... The muscles in the human body are dependent ... the biggest and most significant nervous systems in the ... comprises of peripheral nerves that reside outside of the ... the limbs and hands, as well as other organs, ... due to trauma or physical injury, their functionality is ...
(Date:5/19/2013)... These molecular diagnostics market reports ... Japan, Italy, Germany and France:, ... practice, as well as key economic, regulatory, demographic, ... during the next five years. ,     An ... test formats, detection methodologies, trends in testing automation ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie is ... how to increase memory power naturally and effectively. The ... people re-new their entire health from the inside out. It ... a fatigued mind. In addition, the program helps people keep ... The author claimed that this program can help people overcome ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... Beauty Professionals Encouraged to Share Educational Materials , ... , WASHINGTON, July 23 Look ... to help women cope with the appearance-related changes of cancer treatment, today ... to generate awareness and increase program participation during its 20th anniversary year. ...
... , , Infusion ... LOUISVILLE, Ky., July 23 University of Louisville physicians performed the ... Louisville, KY, on July 17, 2009. The procedure is part of the ... disease. , , The first ...
... , SAN DIEGO, July 23 Orexigen Therapeutics, ... has priced an underwritten public offering of 10,000,000 shares of ... Net proceeds, after estimated underwriting discounts and commissions and estimated ... underwriter a 30-day option to purchase up to an additional ...
... July 23 Estimates place the prevalence of physical disabilities ... the global adult population according to THE ORTHOPAEDIC INDUSTRY ... , "Our sources indicate that ... 25 percent over the past ten years, and those conditions ...
... /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.PK) ( http://www.mitcanada.ca ... that it has been granted a completely new, 8,000 ... from the "China Medical City" in Taizhou city for ... operation facility will harbor all the sub-assembly, final assembly ...
... , , , ... TELEHOUSE America ( www.telehouse.com ... Internet exchanges, and managed IT services, today announced it is offering ... loss prevention (DLP) consulting services as part of its ...
Cached Medicine News:Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Medicine Products: